Celiac Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Celiac Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain, and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren’s syndrome, and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Treatment also involves adhering to strict gluten-free diet.
The Celiac Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Celiac Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 44 molecules, with 44 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Celiac Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Celiac Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Celiac Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ahead Therapeutics SLAllero Therapeutics BV
Amgen Inc
Amyra Biotech AG
Anokion SA
AnTolRx Inc
Barinthus Biotherapeutics Plc
Calypso Biotech SA
Chugai Pharmaceutical Co Ltd
Codexis Inc
Dr. Falk Pharma GmbH
Equillium Inc
Forte Biosciences Inc
IGY Immune Technologies & Life Sciences Inc
ImCyse SA
Immunic Inc
ImmunogenX LLC
ImmunoMolecular Therapeutics LLC
ImmusanT Inc
JN Biosciences LLC
Johnson & Johnson
Kallyope Inc
Mozart Therapeutics Inc
Nemysis Ltd
Parvus Therapeutics Inc
Pfizer Inc
Precigen Inc
Protagonist Therapeutics Inc
RheumaGen LLC
SQZ Biotechnologies Co
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Theravance Biopharma Inc
Theriva Biologics Inc
Topas Therapeutics GmbH
Vactech Oy
Zedira GmbH
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Celiac Disease reports